Enterprise Solutions Webinars
-
Closing The Gap Between Theory And Therapy
1/30/2024
A molecule with great therapeutic potential is only as good as its formulation. For patients, a successful formulation closes the gap between theory and therapy.
-
CDMO Collab with Scorpius BioManufacturing's Steve Lavezoli + Fina Biosolutions' Dr. Andrew Lees
12/27/2023
A new year marks a fresh start for biotech partnerships, and to kick off 2024, we're highlighting a good one. Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. On the Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. If you're considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you won't want to miss this episode.
-
CDMO Collab with Scorpius BioManufacturing's Steve Lavezoli + Fina Biosolutions' Dr. Andrew Lees
12/27/2023
A new year marks a fresh start for biotech partnerships, and to kick off 2024, we're highlighting a good one. Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. On Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. If you're considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you won't want to miss this episode.
-
Biotech Down Under with BiomeBank's Dr. Sam Costello
12/20/2023
Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world. In a segment of biotech that’s been particularly battered of late, that’s a big, big win.
-
Biotech Down Under With BiomeBank's Dr. Sam Costello
12/20/2023
On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind.
-
Optimization-By-Design - A Critical Factor In Viral Vector Scale Up
12/14/2023
Learn how leveraging the expertise and capabilities of an experienced partner is a key factor in optimizing AAV processes using Design of Experiment (DoE), thereby reducing variability and risk.
-
Optimizing mRNA Formulations In A Bottlenecked & Bifurcated Supply Chain
12/5/2023
Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address how to overcome the challenge of screening, developing, and optimizing formulations during preclinical development in a fragmented supply chain and outsourced environment.
-
mRNA Therapeutics: To The Liver, And Beyond!
12/5/2023
This segment from the Bioprocess Online Live event, mRNA Update: Beyond Prophylactic Vaccines, introduces guests, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D., and features Dr. VanCott addressing progress on targets beyond the liver.
-
Adopting Novel Technologies To Improve Monoclonal Antibody Processes
11/15/2023
What are the four new-edge production technologies that better remove impurities, reduce aggregation and improve stability
-
CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt
10/29/2023
What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its CDMO? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?